US 11,945,879 B2
Multispecific antigens binding fragments and multispecific antibodies
Jean Kadouche, Paris (FR); Jean-Pierre Mach, Bellevue (CH); Olivier Michielin, Lausanne (CH); Vincent Zoete, Morges (CH); Justyna Iwaszkiewicz, Geneva (CH); Martine Cerutti, Saint-Christol-lez-Ales (FR); Sylvie Choblet, Ales (FR); and Josee Golay, Bergamo (IT)
Assigned to Jean Kadouche, Paris (FR); Centre National de la Recherche Scientifique, Paris (FR); Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo (IT); and University of Lausanne, Lausanne (CH)
Filed by Centre National de la Recherche Scientifique, Paris (FR); Azienda Ospedaliera Papa Giovanni XXIII, Bergamo (IT); and Universite de Lausanne, Lausanne (CH)
Filed on Aug. 18, 2020, as Appl. No. 16/996,510.
Application 15/463,498 is a division of application No. 14/130,773, granted, now 9,631,031, issued on Apr. 25, 2017, previously published as PCT/IB2012/053482, filed on Jul. 6, 2012.
Application 16/996,510 is a continuation of application No. 15/463,498, filed on Mar. 20, 2017, granted, now 10,815,310.
Claims priority of application No. 11305872 (EP), filed on Jul. 7, 2011.
Prior Publication US 2020/0385490 A1, Dec. 10, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/18 (2006.01); C07K 16/28 (2006.01); C07K 16/46 (2006.01)
CPC C07K 16/468 (2013.01) [C07K 16/2833 (2013.01); C07K 16/2896 (2013.01); C07K 2317/31 (2013.01); C07K 2317/522 (2013.01); C07K 2317/55 (2013.01); C07K 2317/732 (2013.01)] 3 Claims
 
1. A multispecific antibody construct comprising at least two Fab fragments with different CH1 and CL domains, wherein each Fab fragment recognizes a different epitope of interest, and wherein at least one Fab fragment is a mutated Fab fragment that comprises:
the VH and VL domains of an antibody recognizing an epitope of interest;
a CH1 domain which is derived from the CH1 domain of a human immunoglobulin by substitution of the leucine residue at position 143 of said CH1 domain with a glutamine residue and substitution of the serine residue at position 188 of said CH1 domain with a valine residue; and
a CL domain of the kappa type which is derived from the CL-kappa domain of a human immunoglobulin by substitution of the valine residue at position 133 of said CL-kappa domain with a threonine residue and substitution of the serine residue at position 176 of said CL-kappa domain with a valine residue; wherein the position numbers used for the CH1 and CL-kappa domains refer to Kabat numbering.